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Abstract
Purpose: To determine the incidence of and the risk factors for the development of retinal
pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the
treatment of exudative age-related macular degeneration (AMD).
Methods: A retrospective, multicenter, consecutive interventional case series of all
patients with subfoveal exudative AMD treated with intravitreal bevacizumab between
August 2005 and April 2007. The main outcome measures were pre- and post-RPE tear
visual acuity and choroidal neovascular membrane lesion types, incidence of tears, and
time from first injection until development of the tear.
Results: A total of 920 eyes with exudative AMD were treated with intravitreal
bevacizumab. 15 eyes from 15 patients developed a RPE tear for an incidence of 1.6%.
The average patient age was 79 years. 14/15 eyes (93%) had an occult subfoveal
choroidal neovascular membrane. 47% (7/15) of the RPE tears occurred within the first 6
weeks of treatment, and all tears occurred within the first 18 weeks of treatment
initiation. The mean pre-injection visual acuity was 20/100 with a mean post tear visual
acuity of 20/200. In all ten eyes in which the tear involved the fovea, the final visual
acuity was poor. Six of the 15 eyes continued with bevacizumab/ ranibizumab (Lucentis)
injections after tear development, and four of these six eyes continued to have visual
improvement.
Conclusion: RPE tears occur after intravitreal bevacizumab injections for exudative
AMD in approximately 1.6% of eyes and can cause severe vision loss. Maintenance of
therapy may help preserve vision after RPE tear development.
Keywords: bevacizumab, Avastin, retinal pigment epithelium, macular degeneration, tear
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Introduction
Tears of the retinal pigment epithelium (RPE) may occur spontaneously as part of
the natural history of exudative age-related macular degeneration (AMD)1,2. They have
also been reported after treatment for exudative AMD, including thermal laser
photocoagulation and photodynamic therapy (PDT)3-6. There have been reports of RPE
tears after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents,
including pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab
(Avastin)7-17.
Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a recombinant
humanized monoclonal antibody that binds VEGF and inhibits its interaction with
receptors found on endothelial cells. It has been used increasingly as an off-label
treatment for exudative AMD, but without long-term, randomized controlled trials
examining safety and efficacy18-20. It has been hypothesized that intravitreal bevacizumab
causes contraction of choroidal neovascular membranes, thus accelerating RPE tear
development11.
The purpose of this study is to report the incidence of and risk factors for the
development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab
(Avastin) injection for the treatment of exudative AMD.

Methods
After institutional review board approval was obtained, a retrospective review of
all patients treated with intravitreal bevacizumab for subfoveal exudative AMD between
August 2005 and April 2007 by the investigators was performed (The Retina Service of
Wills Eye Institute, Philadelphia, PA; Roy Brod, LLC, Lancaster, PA; and Wilford Hall
Medical Center, San Antonio, TX). Eyes were included if they developed a RPE tear
after initiation of intravitreal bevacizumab therapy. These patients may have had
treatment with thermal laser, photodynamic therapy or pegaptanib sodium prior to
injection of bevacizumab, however, once intravitreal bevacizumab treatment was
initiated, at least three injections were performed before adjuvant therapy (for example
PDT or intravitreal triamcinolone) was added, or before the patient was switched to
ranibizumab (Lucentis, Genentech, South San Francisco, CA). Patients were excluded if
they received intravitreal ranibizumab prior to RPE tear occurrence or if the status of the
RPE could not be assessed prior to initiation of treatment (for example, due to a thick
submacular hemorrhage). Baseline fluorescein angiography (FA) was obtained on all
patients. Baseline optical coherence tomography (OCT) was obtained at the discretion of
the investigator. Follow up examinations were performed at approximately six-week
intervals. Patients were identified with an RPE tear based on clinical examination and
OCT and/or fluorescein angiography as needed. After discovery of the tear, additional
treatment was performed at the discretion of the investigator.
The procedure for intravitreal injection of bevacizumab is briefly as follows.
After informed consent was obtained, the eye was prepped using topical anesthesia and
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5% povidone-iodine. A lid speculum was placed, and 1.25 mg (0.05ml) of bevacizumab
was injected through the pars plana approximately 3.5 mm to 4 mm from the surgical
limbus using a 30-gauge needle. Post-operatively, the patients were instructed to use a
topical antibiotic at the discretion of the investigator. The patient returned approximately
6 weeks later for a follow up examination.
On follow up, the primary outcome measure was Snellen visual acuity. Snellen
visual acuity was converted to the logarithm of the minimal angle of resolution
(LogMAR) for data interpretation. Data was recorded for patient age, gender, eye
involved, baseline vision, baseline lesion type, follow up visual acuities, number of
treatments, date of the RPE tear occurrence, and subsequent treatments, if any. Any
ocular or systemic adverse events were also recorded.
Selected Case Reports

Results
A total of 920 eyes that received a total of 3339 intravitreal injections of
bevacizumab were identified from the practices of the investigators during the study
period. A total of 15 eyes from 15 patients with post-injection tears of the RPE were
found (Table 1). The mean patient age was 79 years (range, 66-93 years) and all patients
were Caucasian. Five patients were males and 10 patients were female. 10 cases
involved the left eye. 14 eyes never had previous treatment for exudative AMD in the
study eye. One patient had received 7 pegaptanib sodium (Macugen) injections prior to
the first bevacizumab injection. The mean follow up period was 26 weeks (range, 12-52
weeks).
14 patients had an occult subfoveal choroidal neovascular membrane. One patient
had a minimally classic membrane. No patient had a classic membrane. Four of the 15
eyes had a serous pigment epithelial detachment at baseline examination. The average
size of the neovascular lesion was 10.31mm2±12.21mm2.
Seven of the 15 RPE tears occurred after the first bevacizumab injection; six of
the 15 occurred after the second injection, and two of 15 occurred after the third
injection.
Baseline median visual acuity was 20/60 and mean visual acuity was 20/100
(range, 20/25-3/200). After occurrence of the tear, the median visual acuity was 20/140,
and mean visual acuity was 20/200 (range, 20/30-3/200). At last follow up, the median
visual acuity was 20/100, and the mean visual acuity was 20/200 (range, 20/25-3/200). At
the discretion of the investigator, six of the 15 eyes received additional bevacizumab or
ranibizumab injections after development of the RPE tear. The mean baseline visual
acuity of these eyes was 20/100 (range, 20/40-3/200). Immediately after the tear, the
mean visual acuity was 20/100 (range, 20/50-20/200), and mean visual acuity at last
follow up was 20/160 (range 20/25-3/200).
Discussion
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Off-label intravitreal injection of bevacizumab is used to treat a number of ocular
conditions, including proliferative diabetic retinopathy, diabetic macular edema, retinal
vein obstructions, neovascular glaucoma, and choroidal neovascular membranes due to
myopia and age-related macular degeneration21-27. Although seemingly well tolerated
and efficacious for the treatment of exudative AMD, intravitreal bevacizumab has been
associated with tears of the retinal pigment epithelium in several case reports as well as in
recent, larger case series 8-11, 15-17.
We report a 1.6% incidence of RPE tears in association with intravitreal
bevacizumab injections. Furthermore, nearly half of these cases occurred after the first
bevacizumab injection (7/15) and all occurred within 18 weeks of starting treatment.
Chan and colleagues found that 73% of the RPE tears occurred after the first injection.
This may be due to the fact that 8/22 of their patients were treated with 2.5 mg of
bevacizumab in contrast to the 1.25 mg dose used for our patients. In their paper, 2.6%
of patients that received 2.5mg of bevacizumab developed a RPE tear, versus 2.2% of
patients in the 1.25mg group. This difference, however, was not statistically significant.
Additionally, 7/22 eyes in their study versus only 1/15 eyes in our study received prior
treatment for exudative AMD. This may have predisposed some eyes to RPE tear
development. In this series, 14/15 RPE tears were seen in occult neovascular AMD. In
contrast to the study by Ronan and colleagues, only 27% (4/15) in our study had a
significant serous pigment epithelial detachment (PED)16. None of these tears occurred
in eyes with a classic choroidal neovascular membrane, but as only 10% of exudative
AMD have classic membranes, this result may simply reflect the relative incidence of
choroidal neovascular types and not risk for RPE tear development. No significant
systemic or ocular side effects were evident.
Overall, after occurrence of the RPE tear, most patients experienced significant
visual loss. However, in eyes in which the tear spared the fovea, the visual results could
be good and there could even be visual improvement. Six eyes continued to receive
intravitreal injection of ranibizumab or bevacizumab after RPE tear development; in four
of these six eyes vision continued to improve, supporting maintenance of therapy as
suggested by Chan et al15. There were no consistent findings to help determine which
eyes would benefit from continued treatment after RPE tear development, however
continued treatment with an anti-VEGF agent should be considered in patients in whom
the RPE tear spares some or all of the fovea or in whom the vision is still subjectively
good.
Tears of the RPE have been reported as part of the natural history of AMD, as
well as after thermal laser, photodynamic therapy, intravitreal pegaptanib sodium,
ranibizumab and bevacizumab injections. Although the ANCHOR and MARINA studies
reported no cases of RPE tears with ranibizumab (from a total of 758 eyes), there have
been anecdotal reports of its occurence12, 14, 28, 29. In the photodynamic therapy trials with
Visudyne (Novartis) (TAP and VIP studies) the incidence of RPE tears was not
commented upon30, 31. A recent report found a 13% incidence RPE tears after
photodynamic therapy with verteporfin for choroidal neovascular membrane associated
with pigment epithelial detachment32.
This report is limited because it is a retrospective study with no control group. It
is possible that other patients had small or otherwise undetected RPE tears. If other
patients had RPE tears that were missed, the incidence of tears of the RPE could be
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higher than reported here. Patients started on bevacizumab and then switched to
ranibizumab after their first intravitreal injection were excluded from analysis which
could also cause underestimation of the risk.
In conclusion, this study demonstrates a 1.6% incidence of RPE tears after
intravitreal injection of bevacizumab, which is higher than that seen in the randomized
controlled trials with ranibizumab or Visudyne. Patients should be counseled that RPE
tears may occur as a consequence of bevacizumab therapy, but may be simply part of the
underlying disease process. Patients with occult choroidal neovascular membranes and
those with a large serous PED may be at higher risk of developing this complication and
should be counseled appropriately. Clinicians should also be aware that some patients
benefit from continued treatment with an anti-VEGF agent even after development of the
tear. Larger randomized, controlled clinical studies with long-term follow-up will be
necessary to further establish whether intravitreal bevacizumab injection increases the
incidence of RPE tears in eyes with exudative AMD.
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Figure Legend
Figure 1: a) There is a subfoveal serous choroidal neovascular membrane in case 7
(arrows). b) The FA demonstrates the fibrovascular PED centrally with a surrounding
serous PED (arrows). c) Two weeks after her first intravitreal bevacizumab injection, she
developed a tear of the RPE that spared the fovea (arrows). d) Repeat FA demonstrates a
tear of the RPE that spared the fovea. With subsequent ranibizumab injections, the
patient’s vision improved to 20/25.

